Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cardiovascular endocrinology

Growth hormone in CVD prediction—a tall order?

Nature Reviews Endocrinology volume 11, pages 11–13 (2015)Cite this article

Subjects

Endocrine and metabolic pathways are a rich ground in which to examine the prognostic significance of biomarkers of cardiovascular risk. Whereas numerous biomarkers for prediction of cardiovascular disease have emerged in the past decade, far fewer have transitioned into clinical practice. Will growth hormone fulfill its potential?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hallengren, E. et al. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmö diet and cancer study. J. Am. Coll. Cardiol. 64, 1452–1460 (2014).

    Article  CAS  Google Scholar 

  2. Isgaard, J., Arcopinto, M., Karason, K. & Cittadini, A. GH and the cardiovascular system: an update on a topic at heart. Endocrine http://dx.doi.org/10.1007/s12020-014-0327-6.

  3. Yuan, M. J., Huang, H. & Huang, C. X. Potential new role of the GHSR-1a-mediated signaling pathway in cardiac remodeling after myocardial infarction. Oncol. Lett. 8, 969–971 (2014).

    Article  CAS  Google Scholar 

  4. Abs, R. et al. Determinants of cardiovascular risk in 2,589 hypopituitary GH-deficient adults—a KIMS database analysis. Eur. J. Endocrinol. 155, 79–90 (2006).

    Article  CAS  Google Scholar 

  5. Bulow, B., Hagmar, L., Eskilsson, J. & Erfurth, E. M. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J. Clin. Endocrinol. Metab. 85, 574–584 (2000).

    CAS  PubMed  Google Scholar 

  6. Coschigano, K. T. et al. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144, 3799–3810 (2003).

    Article  CAS  Google Scholar 

  7. Maison, P. et al. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ 316, 1132–1133 (1998).

    Article  CAS  Google Scholar 

  8. McGeechan, K., Macaskill, P., Irwig, L. & Bossuyt, P. M. An assessment of the relationship between clinical utility and predictive ability measures and the impact of mean risk in the population. BMC Med. Res. Methodol. 14, 86 (2014).

    Article  Google Scholar 

  9. Bidlingmaier, M. & Freda, P. U. Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences. Growth Horm. IGF Res. 20, 19–25 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, RW-453, Boston, 02215, MA, USA

    Connie W. Tsao

  2. The Framingham Heart Study, 73 Mount Wayte Avenue, Suite 2, Framingham, 01702, MA, USA

    Ramachandran S. Vasan

Authors
  1. Connie W. Tsao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramachandran S. Vasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie W. Tsao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsao, C., Vasan, R. Growth hormone in CVD prediction—a tall order?. Nat Rev Endocrinol 11, 11–13 (2015). https://doi.org/10.1038/nrendo.2014.204

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2014.204

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing